$MLAB SEC Filings

Filed On	Filing
27 Oct 2026	SCHEDULE 13G/A
13 Oct 2026	8-K: Cost Associated with Exit or Disposal Activities; Regulation FD Disclosure Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
09 Oct 2026	SCHEDULE 13G
11 Sep 2026	Form 4: Capone Mark Christopher, Director Granted 2,423 Restricted Stock Units - 4
11 Sep 2026	Form 4: Ladiwala Shiraz Shabanali, Director Granted 2,510 Restricted Stock Units - 7
11 Sep 2026	Form 4: Alltoft Jennifer Sadie, Director Granted 1,774 Restricted Stock Units - 10
11 Sep 2026	Form 4: Hall Shannon, Director Granted 1,774 Restricted Stock Units - 9
11 Sep 2026	Form 4: Sullivan John James, Director Granted 1,774 Restricted Stock Units - 11
11 Sep 2026	Form 4: Tripeny R Tony, Director Granted 1,774 Restricted Stock Units - 5
08 Sep 2026	8-K: Submission of Matters to a Vote of Security Holders On September 8, 2026, the Company held its annual meeting of shareholders (the “Annual Meeting”). Holders of 5,595,869 shares of Mesa’s common stock were entitled to vote, of which 4,872,692 shares were represented in person or by proxy ...
27 Aug 2026	144
21 Aug 2026	144
17 Aug 2026	Form 4: Capone Mark Christopher, Director Received 2,784 shares by exercise or conversion
17 Aug 2026	Form 4: Alltoft Jennifer Sadie, Director Received 2,784 shares by exercise or conversion
17 Aug 2026	Form 4: Ladiwala Shiraz Shabanali, Director Received 3,810 shares by exercise or conversion
17 Aug 2026	Form 4: Hall Shannon, Director Received 2,784 shares by exercise or conversion
17 Aug 2026	Form 4: Tripeny R Tony, Director Received 2,784 shares by exercise or conversion
17 Aug 2026	Form 4: Sullivan John James, Director Received 2,784 shares by exercise or conversion
17 Aug 2026	Form 4: Sullivan John James, Director Sold 7,093 shares ($800K)
17 Aug 2026	Form 4: Kadia Siddhartha, President and CEO Bought 7,093 shares ($800K)

Comments